Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.
Introduction Uptake of preventive therapies for breast cancer is low. We examined whether women at increased risk of breast cancer can be categorized into groups with similar medication beliefs, and whether belief group membership was prospectively associated with uptake of preventive therapy. Patients and Methods Women (n = 732) attending an appointment to discuss breast cancer risk were approached; 408 (55.7%) completed the Beliefs About Medicines and the Perceived Sensitivity to Medicines questionnaires. Uptake of tamoxifen at 3 months was reported in 258 (63.2%). The optimal number of belief groups were identified using latent profile analysis. Results Uptake of tamoxifen was 14.7% (38/258). One in 5 women (19.4%; 78/402) reported a strong need for tamoxifen. The model fit statistics supported a 2-group model. Both groups held weak beliefs about their need for tamoxifen for current and future health. Group 2 (38%; 154/406 of the sample) reported stronger concerns about tamoxifen and medicines in general, and stronger perceived sensitivity to the negative effects of medicines compared with group 1 (62%; 252/406). Women with low necessity and lower concerns (group 1) were more likely to initiate tamoxifen (18.3%; 33/180) than those with low necessity and higher concerns (group 2) (6.4%; 5/78). After adjusting for demographic and clinical factors, the odds ratio was 3.37 (95% confidence interval, 1.08-10.51; P = .036). Conclusion Uptake of breast cancer preventive therapy was low. A subgroup of women reported low need for preventive therapy and strong medication concerns. These women were less likely to initiate tamoxifen. Medication beliefs are targets for supporting informed decision-making.
No abstract
Background: Patients diagnosed with primary breast cancer (BC) often have a couple weeks interval between diagnosis and definitive surgery. This time window provides the opportunity for assessing biological drug effects in a treatment naive population. The EPHOS-B trial was designed to measure the effect of pre-operative anti-HER2 therapy on proliferation and apoptosis in HER2+ BC patients. Patients & methods: EPHOS-B is a multicentre, 2-part randomized trial in patients with operable newly diagnosed HER2+ primary BC. In Part 1 patients were randomized (1:2:2) to no perioperative treatment (control), trastuzumab only or lapatinib only (11 days pre-operative therapy). Emerging evidence on the efficacy and safety of combination anti-HER2 therapy led to Part 2 in which patients were allocated to control, perioperative trastuzumab only or lapatinib and trastuzumab (1:1:2). The IDMC have agreed release of data from lapatinib Part 1 patients only. Tissue samples were taken at the time of diagnostic core biopsy and surgery, and analysed centrally for Ki67, apoptosis (activated caspase 3), PgR, HER3 and Bcl2 by immunohistochemistry (IHC). Local ER and PgR status were also recorded. Primary endpoint is change in Ki67 and/or apoptosis. Response is defined by a drop in Ki67 of ≥30% or a rise in apoptosis of ≥30% from baseline. Results: Between Nov-2010 and Jul-2013, 51 patients (pts) were allocated to perioperative lapatinib, with 49 (96.1%) receiving at least 1 dose. All pts were HER2+ (90% 3+ by IHC and 10% amplified by FISH, locally assessed) at entry. Median age was 51 years (IQR 48-60); 65% had tumours >2cm and 51% were grade 3 at surgery. According to local assessment, 61% were ER+ and 43% PgR+. Only 2 pts (4%) had a dose reduction and 1 pt (2%) discontinued lapatinib in the 3 days prior to surgery due to toxicity (rash, 3pts; nausea, 1pt). There were no delays in surgery. Paired samples were valid for analysis in 43/51 (84%); invalid pairs were mostly due to inadequate samples for scoring. Overall, 67% (95% CI: 52% to 81%) of pts demonstrated a ≥30% fall in Ki67 whilst a ≥30% rise in apoptosis was observed only in 30% of pts (95% CI: 17% to 46%). When assessed as continuous variables, Ki67 fell significantly from pre-treatment but there was no significant change in apoptosis detected (results in table). No correlation was observed between Ki67 change and change in apoptosis (p=0.5). Neither HER-3 expression nor BCL2 predicted response. ER- HER2+, n=18ER+ PR- HER2+, n=7ER+PR+HER2+, n=17All, n=43*Ki67 % change from pre treatment-51% (-69% to -21%), p<0.001-53% (-78% to -11%), p=0.02-38% (-58% to -24%), p<0.001-45% (-57% to -32%), p<0.001Apoptosis % change from pre treatment-24% (-37% to +30%), p=0.27-13% (-48% to +125%), p=0.61-13% (-65% to +43%), p=0.19 Median % change (95% confidence interval), p-value: Wilcoxon signed-rank test. *1 pt missing ER status Conclusion: EPHOS-B demonstrates that ∼11 days' lapatinib has a marked anti-proliferative effect in HER2+ve breast cancers. The trial is ongoing and when complete will provide a definitive analysis of the relative biological effects of perioperative treatment with different anti-HER2 therapies (trastuzumab, lapatinib and their combination) in patients with HER2+ BC. Citation Format: Bundred N, Cameron D, Kalaitzaki E, Morley R, Cramer A, Webster-Smith M, Narayanan S, Brunt M, Horgan K, Hanby A, Ooi J, Hong A, Naik J, Evans A, Shaaban A, Bliss J. Effects of perioperative lapatinib in early HER2+ breast cancer - The UK EPHOS-B trial (CRUK/08/002). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD5-06.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.